Not Signed In - MacuSight(TM) Initiates First Phase I Study Of Novel Ophthalmic Drug Candidate
Wed, 27 Sep 2006 07:00 AM EST
... MacuSight(TM), Inc., a developer of innovative therapeutics for the treatment of severe oculardiseases and conditions, today announced the initiation of a Phase I studyof its lead product candidate in patients with diabetic macular edema(DME). [click link for full article] ...
Related Topics
- Cyclosporine Ophthalmic
- Polymyxin B, Bacitracin, and Neomycin Ophthalmic Ointment
- Drug Safety
- Prescription Drugs
- Urinalysis
- Drug Side Effects
- Drug Abuse
- Trimethoprim and Polymyxin Ophthalmic
- Drug Information
- Prescription Drug Abuse
- Prescription Drugs Abuse
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Diclofenac Ophthalmic
- Dexamethasone Ophthalmic
- Gatifloxacin Ophthalmic
- Galantamine
- Tobramycin and Dexamethasone Ophthalmic
- Hydrocortisone, Neomycin, and Polymyxin Ophthalmic Drops
- Clinical Trials
email this page
print this page
bookmark this page
feedback on this page
